Roche Ventures Further into Alzheimer's Research: Trontinemab in Focus
Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or preventing Alzheimer's symptoms. The drug aims to cross the blood-brain barrier more effectively, targeting those at risk of cognitive decline. Meanwhile, rivals such as Eli Lilly show progress with their own Alzheimer's treatments.
Swiss drugmaker Roche Holding has announced its plans to investigate the potential of an experimental medicine, Trontinemab, in delaying or preventing Alzheimer's disease symptoms. This initiative forms a significant part of Roche's expanding development program focused on combating the neurodegenerative condition.
Trontinemab has been specifically designed to transport across the blood-brain barrier — a crucial protective layer preventing harmful particles from entering the brain — increasing the presence of the drug in the brain. This advancement comes amid competitive progress from pharmaceutical rivals like Eli Lilly, whose drug Kisunla recently received a nod for certain patient treatments from the European Medicines Agency.
The existing treatments for Alzheimer's, which include Eisai and Biogen's Leqembi as well as Lilly's Kisunla, function primarily by targeting and clearing amyloid beta protein clumps in the brain. However, these treatments are often accompanied by high costs and the significant risk of severe side effects such as brain swelling and hemorrhage.
Google News